

CLAIMS:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide having a sequence encoded as the polypeptide of SEQ ID NO:2;
 - (b) a polynucleotide that is a variant of naturally occurring (a); and
 - (c) a polynucleotide able to hybridize with (a) and having at least 85% homology with (a).
2. A polynucleotide of Claim 1, wherein said polynucleotide is DNA.
3. A polynucleotide of Claim 1, wherein said polynucleotide is RNA.
4. A polynucleotide of Claim 1, wherein said polynucleotide is genome DNA.
5. A polynucleotide of Claim 1, wherein said polynucleotide has the sequence set forth in SEQ ID NO:1.
6. A polynucleotide of Claim 1, wherein said polynucleotide has the sequence set forth as nucleotides 107 to 1219 of SEQ ID NO:1.
7. A polynucleotide of Claim 2, wherein said nucleotide has a sequence encoded as the polypeptide of SEQ ID NO:2.
8. A vector comprising the DNA of Claim 2.
9. A host cell transformed or transfected by the vector of Claim 8.
10. A method for producing polypeptide which includes said DNA-encoded polypeptide expressed in the host cell of Claim 9.
11. A polypeptide selected from the group consisting of:
 - (a) a polypeptide having an inferred amino acid sequence set forth in SEQ ID NO:2;
 - (b) a polypeptide which is an active fragment, analog or derivative of (a); and
 - (c) a polypeptide having at least 85% homology with the amino acid sequence

set forth in SEQ ID NO:2.

12. An antibody of the polypeptide of Claim 11.
13. A compound which inhibits the activation of the polypeptide of Claim 11.
14. A pharmaceutical composition containing an effective amount of the polypeptide of Claim 11 or its active fragment, and one or more pharmaceutically acceptable vectors or excipients.
15. A use for the polypeptide of Claim 11 in the preparation of pharmaceutical compositions used to treat cardio-cerebral-vascular diseases.
16. A method for treating patients requiring Fwa267, comprising administering a therapeutically effective dosage of the polypeptide of Claim 11 to a patient.
17. A method of Claim 16, wherein said patient is provided DNA encoding said polypeptide, and said polypeptide is expressed within the body of said patient.
18. A method for diagnosing disease or susceptibility to disease comprising assaying for a mutation of the polynucleotide of Claim 1.
19. A method for diagnosing disease, comprising analyzing whether or not a polypeptide of Claim 11 exists in a sample from a host cell.